• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Recursion Pharmaceuticals Inc Cl A (NQ: RXRX )

    6.930 -0.040 (-0.57%)
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 7, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Recursion Pharmaceuticals Inc Cl A

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    13 14 Next >
    Cathie Wood Owns These 2 AI Stocks. Should You?
    One looks like a solid option. The other one, not so much. 
    Via The Motley Fool
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    Is Recursion Pharmaceuticals Stock a Millionaire-Maker?
    Recursion Pharmaceuticals hopes to transform the healthcare industry with the help of AI. 
    Via The Motley Fool
    How Is The Market Feeling About Recursion Pharmaceuticals?
    Via Benzinga
    Power of Recursion OS on Display at Genome Scale in Nature Genetics Paper Detailing Potential Limitation of CRISPR Gene Editing Tool
    Published open-access today in Nature Genetics, “High-resolution genome-wide mapping of chromosome-arm-scale truncations induced by CRISPR–Cas9 editing” identifies novel evidence of a proximity bias in... 
    From Recursion Pharmaceuticals
    Via GlobeNewswire
    Recursion Pharm Stock Sees Relative Strength Rating Rise To 84
    On Tuesday, Recursion Pharm stock had its Relative Strength (RS) Rating upgraded to 84, up from 78 a day earlier. 
    Via Investor's Business Daily
    Demystifying Recursion Pharmaceuticals: Insights From 4 Analyst Reviews
    Via Benzinga
    (RXRX) - Analyzing Recursion Pharmaceuticals's Short Interest
    Via Benzinga
    2 Cathie Wood Biotech Stocks That Could Be Worth the Risk
    You don't need to buy her picks, but it's worth understanding them. 
    Via The Motley Fool
    Largest Clinical-Stage BioTech Drug Stocks Declined Slightly Last Week
    This article highlights the performances last week and MTD of the 10 clinical-stage AI-powered and psychedelic compound-based small cap drug discovery companies along with their areas of focus in our... 
    Via Talk Markets
    Recursion Appoints Robert Hershberg M.D., Ph.D, as New Chair of the Board
    Dr. Hershberg is a current board member with over 25 years of experience as a physician, scientist, and entrepreneur 
    From Recursion Pharmaceuticals
    Via GlobeNewswire
    2 Stocks That Could 10x by 2035
    These stocks are very promising, but it's important to consider the downside, too. 
    Via The Motley Fool
    Jim Cramer Offers His Take On Corning, Calls This Healthcare Stock A 'Terrific Spec'
    Jim Cramer says Corning has "not been able to generate the kind of return that I've wanted"; calls Recursion a "terrific spec" 
    Via Benzinga
    A $50B AI Drug Discovery Revolution Has Begun - Here Are 6 Stocks To Consider Investing In
    The drug development process is very expensive and time-consuming which creates a huge shortage in drug candidates and programs but the advent of AI can significantly shorten and cheapen this process... 
    Via Talk Markets
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    What's the Difference Between Biotech Stocks and TechBio Stocks?
    A few enterprising businesses are marketing themselves differently. 
    Via The Motley Fool
    Sony Group Posts Upbeat Earnings, Joins GameStop, Paysafe And Other Big Stocks Moving Higher On Tuesday
    Via Benzinga
    The Next Drug You Take May be Designed By A.I.
    Three stocks could give investors a better way to tap into A.I.'s future potential inside drug development, an industry that is set to grow at 29.6% until 2030 
    Via MarketBeat
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    Recursion Pharmaceuticals Stock Surges 10% As Nvidia-Powered Supercomputer Completion Sparks Investor Optimism
    Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) made waves Monday afternoon not only with the announcement of its groundbreaking BioHive-2 supercomputer but also with a notable surge in its stock... 
    Via Benzinga
    Largest Clinical-Stage BioTech Drug Stocks Declined 3% Last Week
    Via Talk Markets
    Why Akoustis Technologies Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Via Benzinga
    GameStop, Squarespace, Incyte And Other Big Stocks Moving Higher On Monday
    Via Benzinga
    Recursion Announces Completion of NVIDIA-Powered BioHive-2, the Largest Supercomputer in Pharmaceutical Industry
    BioHive-2, an NVIDIA DGX SuperPOD with NVIDIA DGX H100 systems, ranked #35 in the TOP500 list of the most powerful supercomputers in the world across all industries as of May 2024. 
    From Recursion Pharmaceuticals
    Via GlobeNewswire
    Cathie Wood Is Buying This Under-the-Radar AI Stock
    This company has massive upside potential, but that's not the whole story. 
    Via The Motley Fool
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    RXRX Stock Earnings: Recursion Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024
    RXRX stock results show that Recursion Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
    Via InvestorPlace
    Nvidia-Backed Recursion Pharmaceuticals Stock Is Up On Q1 Earnings: Everything You Need To Know
    Recursion reported first-quarter revenue of $13.491 million, which beat analyst estimates of $12.65 million, according to Benzinga Pro. The company reported a quarterly loss of 39 cents per share,... 
    Via Benzinga
    Nvidia Favorite SoundHound AI Delivers Beat-And-Raise Report
    SoundHound AI, which counts Nvidia as an investor, beat estimates for the first quarter and with its sales guidance. SOUN stock rose. 
    Via Investor's Business Daily
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    Recursion Provides Business Updates and Reports First Quarter 2024 Financial Results
    From Recursion Pharmaceuticals
    Via GlobeNewswire
    Clinical-Stage BioTech Drug Stocks Portfolio Jumped 7% In First Week Of May
    We look at the performance of 10 clinical-stage AI-powered and psychedelic compound-based small cap drug discovery companies during the first week of May and YTD. 
    Via Talk Markets
    Recursion to Report First Quarter 2024 Business Updates and Financial Results on May 9
    Company to host public L(earnings) Call on May 9 at 5:00 pm ET 
    From Recursion Pharmaceuticals
    Via GlobeNewswire
    Recursion to Participate in Upcoming Investor Conferences
    From Recursion Pharmaceuticals
    Via GlobeNewswire
    Altitude Lab Secures Small Business Administration Growth Fund Accelerator Grant to Launch Horizon, a Commercialization Partnering Program
    The grant designates Altitude Lab as a top acceleration program for biotechnology startups 
    From Recursion Pharmaceuticals
    Via GlobeNewswire
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    13 14 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.